TY - JOUR
T1 - Nonandrogenic anabolic hormones predict risk of frailty
T2 - European male ageing study prospective data
AU - EMAS Study Group
AU - Swiecicka, Agnieszka
AU - Lunt, Mark
AU - Ahern, Tomás
AU - O'Neill, Terence W.
AU - Bartfai, György
AU - Casanueva, Felipe F.
AU - Forti, Gianni
AU - Giwercman, Aleksander
AU - Han, Thang S.
AU - Lean, Michael E.J.
AU - Pendleton, Neil
AU - Punab, Margus
AU - Slowikowska-Hilczer, Jolanta
AU - Vanderschueren, Dirk
AU - Huhtaniemi, Ilpo T.
AU - Wu, Frederick C.W.
AU - Rutter, Martin K.
N1 - Funding Information:
EMAS is funded by the Commission of the European Communities Fifth Framework Program "Quality of Life and Management of Living Resources" Grant QLK6-CT-2001-00258 and is facilitated by the Manchester Biomedical Research Centre and the National Institute for Health Research Greater Manchester Clinical Research Network. Additional support was provided by the Arthritis Research UK Centre for Epidemiology and the National Institute for Health Research and the Manchester Biomedical Research Centre. A.S. and F.W. were supported by Medical Research Council Grant MR/K025252/1 in this study.
Publisher Copyright:
© Copyright 2017 Endocrine Society.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Context: Low levels of nonandrogenic anabolic hormones have been linked with frailty, but evidence is conflicting and prospective data are largely lacking. Objective: To determine associations between nonandrogenic anabolic hormones and prospective changes in frailty status. Design/Setting: A 4.3-year prospective observational study of community-dwelling men participating in the European Male Ageing Study. Participants: Men (n = 3369) aged 40 to 79 years from eight European centers. Main Outcome Measures: Frailty status was determined using frailty phenotype (FP; n = 2114) and frailty index (FI; n = 2444). Analysis: Regression models assessed relationships between baseline levels of insulinlike growth factor 1 (IGF-1), its binding protein 3 (IGFBP-3), dehydroepiandrosterone sulfate (DHEA-S), 25-hydroxyvitamin D (25OHD), and parathyroid hormone (PTH), with changes in frailty status (worsening or improving frailty). Results: The risk of worsening FP and FI decreased with 1 standard deviation higher IGF-1, IGFBP-3, and 25OHD in models adjusted for age, body mass index, center, and baseline frailty [IGF-1: odds ratio (OR) for worsening FP, 0.82 (0.73, 0.93), percentage change in FI, -3.7% (-6.0, -1.5); IGFBP-3: 0.84 (0.75, 0.95), -4.2% (-6.4, -2.0); 25OHD: 0.84 (0.75, 0.95); -4.4%, (-6.7, -2.0)]. Relationships between IGF-1 and FI were attenuated after adjusting for IGFBP-3. Higher DHEA-S was associated with a lower risk of worsening FP only in men >70 years old [OR, 0.57 (0.35, 0.92)]. PTH was unrelated to change in frailty status. Conclusions: These longitudinal data confirm the associations between nonandrogenic anabolic hormones and the changes in frailty status. Interventional studies are needed to establish causality and determine therapeutic implications.
AB - Context: Low levels of nonandrogenic anabolic hormones have been linked with frailty, but evidence is conflicting and prospective data are largely lacking. Objective: To determine associations between nonandrogenic anabolic hormones and prospective changes in frailty status. Design/Setting: A 4.3-year prospective observational study of community-dwelling men participating in the European Male Ageing Study. Participants: Men (n = 3369) aged 40 to 79 years from eight European centers. Main Outcome Measures: Frailty status was determined using frailty phenotype (FP; n = 2114) and frailty index (FI; n = 2444). Analysis: Regression models assessed relationships between baseline levels of insulinlike growth factor 1 (IGF-1), its binding protein 3 (IGFBP-3), dehydroepiandrosterone sulfate (DHEA-S), 25-hydroxyvitamin D (25OHD), and parathyroid hormone (PTH), with changes in frailty status (worsening or improving frailty). Results: The risk of worsening FP and FI decreased with 1 standard deviation higher IGF-1, IGFBP-3, and 25OHD in models adjusted for age, body mass index, center, and baseline frailty [IGF-1: odds ratio (OR) for worsening FP, 0.82 (0.73, 0.93), percentage change in FI, -3.7% (-6.0, -1.5); IGFBP-3: 0.84 (0.75, 0.95), -4.2% (-6.4, -2.0); 25OHD: 0.84 (0.75, 0.95); -4.4%, (-6.7, -2.0)]. Relationships between IGF-1 and FI were attenuated after adjusting for IGFBP-3. Higher DHEA-S was associated with a lower risk of worsening FP only in men >70 years old [OR, 0.57 (0.35, 0.92)]. PTH was unrelated to change in frailty status. Conclusions: These longitudinal data confirm the associations between nonandrogenic anabolic hormones and the changes in frailty status. Interventional studies are needed to establish causality and determine therapeutic implications.
UR - http://www.scopus.com/inward/record.url?scp=85026921744&partnerID=8YFLogxK
U2 - 10.1210/jc.2017-00090
DO - 10.1210/jc.2017-00090
M3 - Article
C2 - 28609827
AN - SCOPUS:85026921744
SN - 0021-972X
VL - 102
SP - 2798
EP - 2806
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 8
ER -